With respect to some of those really serious resistance patterns — MRSA and vancomycin resistance — as well and some of the serious things that happen within the hospitals, from nosocomial infections to people who get ill when they go into the hospital, we have done a fair bit of work with the hospital community in helping them identify ways to prevent those things from happening, such as usage guidelines.

While some costs have come down, the cost of the cheapest second-line regimens needed when someone develops a resistance to the first-line treatment ranges up to U.S. $1,000 per patient per year.

Action (EU and Member States) Explore the possibilities to improve policies and develop measures which address biodiversity loss and climate change in an integrated manner to fully exploit co-benefits and avoid ecosystem feedbacks that accelerate global warming Develop guidelines and a set of tools (guidance and exchange of best practices) by the end of 2009 to ensure that the River Basin Management Plans (RBMP) are climate-proofed Ensure that climate change is taken into account in the implementation of the Floods Directive. Assess the need for further measures to enhance water efficiency in agriculture, households and buildings Explore ...[+++] the potential for policies and measures to boost ecosystem storage capacity for water in Europe Draft guidelines by 2010 on dealing with the impact of climate change on the management of Natura 2000 sites |

A line is interoperable from the cross wind point of view if cross wind safety is ensured for an interoperable train running along that line under the most critical operational conditions.

b) Development of guidelines to satisfy the requirements for the resistance section in a regulatory dossier for antimicrobial agents, with particular emphasis on a description of the testing aimed at establishing the likelihood of resistance development to novel antimicrobial agents, i.e pre-authorisation sensitivity testing guidelines.

d) Development of definitive guidelines for antimicrobial prophylaxis, combination therapies, in-feed and water mass medication, given that resistance is driven by the volume of active use and the route of administration.